Preview Mode Links will not work in preview mode

Apr 13, 2020

Hepatocellular Carcinoma Update, Issue 1, 2020 — Part 2: Our interview with Dr Greten highlights the following topics as well as cases from his practice:

  • Adjuvant treatment of HCC: Prospect for immunotherapy (00:00)
  • Immune landscape of the liver and role of the microbiome (04:18)
  • Ongoing trials evaluating immunotherapy in the (neo)adjuvant setting for patients with HCC (07:04)
  • Role of immunotherapy and targeted therapy in the management of cholangiocarcinoma (09:49)
  • Mechanism for the synergy between immune checkpoint inhibitors and anti-angiogenic therapies (11:16)
  • Perspective on an antibody- versus a tyrosine kinase inhibitor-based approach to targeting VEGF (14:00)
  • Development of shellfish allergy after exposure to dual immune checkpoint blockade with durvalumab and tremelimumab (17:03)
  • Spectrum of immune-related adverse events associated with checkpoint inhibitors (18:47)
  • Background and design of the Phase III IMbrave150 trial (20:03)
  • Exclusion of patients with bleeding or high risk of bleeding with untreated varices from the IMbrave150 trial (21:34)
  • IMbrave150: Activity and tolerability of atezolizumab/bevacizumab versus sorafenib (24:32)
  • Historical response rates with single-agent tyrosine kinase inhibitors or anti-PD-1/PD-L1 antibodies (27:46)
  • Potential clinical role of atezolizumab/bevacizumab as first-line therapy for patients with advanced HCC (28:56)
  • Selection and sequencing of therapies for patients with HCC (31:27)
  • Ongoing investigation of immune checkpoint inhibitor combinations (34:05)
  • Activity of immune checkpoint inhibitors in patients with HCC (35:57)
  • Case: A man in his mid-60s with a history of hepatitis C receives cabozantinib for metastatic HCC after experiencing disease progression on lenvatinib and pembrolizumab (38:19)
  • Side effects associated with sorafenib and lenvatinib (41:11)
  • Efficacy and tolerability of pembrolizumab for HCC (43:51)
  • Approach to first- and second-line treatment for HCC (47:56)
  • Case: A man in his early 40s with chronic hepatitis B and metastatic HCC has no evidence of disease after treatment with pembrolizumab and surgical resection (50:55)
  • Case: A man in his mid-40s with uncontrolled hepatitis C develops transaminitis after treatment with sorafenib for HCC (55:14)

CME information and select publications